Elevation of Serum C-Reactive Protein in Patients With OAB and IC/BPS Implies Chronic Inflammation in the Urinary Bladder

被引:75
作者
Chung, Shiu-Dong [2 ]
Liu, Hsin-Tzu [1 ,3 ]
Lin, Heng [3 ]
Kuo, Hann-Chorng [1 ]
机构
[1] Tzu Chi Univ, Buddhist Tzu Chi Gen Hosp, Dept Urol, Hualien, Taiwan
[2] Far Eastern Mem Hosp, Dept Urol, Taipei, Taiwan
[3] Tzu Chi Univ, Inst Pharmacol & Toxicol, Hualien, Taiwan
关键词
inflammation; interstitial cystitis; overactive bladder symptoms; NERVE GROWTH-FACTOR; DETRUSOR WALL THICKNESS; OVERACTIVE BLADDER; TRACT SYMPTOMS; COMBINATION THERAPY; FACTOR LEVEL; MEN; WOMEN; PREVALENCE; COULD;
D O I
10.1002/nau.20938
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: Chronic inflammation has been implicated in the development of overactive bladder (OAB) and interstitial cystitis/ bladder pain syndrome (IC/BPS). An elevation of C-reactive protein (CRP) has been associated with chronic inflammation and lower urinary tract symptoms. This study aims to elucidate the association between CRP and OAB or IC/BPS. Methods: Serum CRP and urinary nerve growth factor (NGF) levels were examined in 70 patients with OAB (n 22) or IC/BPS (n 48) andcompared with 33 normal controls. Data ofserum CRP and urinaryNGFlevels were comparedamongthe controls, IC/PBS, and OAB. The Spearmen correlation analysis test and ANOVA(Kruskal-Wallis) test were used for statistical analysis with P < 0.05 considered significant. Results: Serum CRP levels were significantly higher in subjects with OAB (1.83 W 2.30 mg/L vs. 0.59 W 0.40 mg/L, P 0.012) or IC/BPS (1.76 +/- 3.56 mg/L vs. 0.59 +/- 0.40 mg/L, P 0.049) than in controls. No significant difference in CRP level was noted between patients with OAB and IC/BPS (P = 0.43). In a subgroup analysis, patients of OAB wet had higher serum CRP level than that of OAB dry (2.95 +/- 3.08 mg/L vs. 0.90 +/- 0.52 mg/L); however, the difference did not reach statistical significance (P 0.34). The CRP between OAB wet and OAB patients with medical disease was not significantly different. There was no significant correlation between serum CRP and urinary NGF levels in the controls or patients withOABor IC/BPS, except in theOABpatients with aCRPlevel > 3 mg/L. Conclusions: Our data support the association between chronic inflammation of the urinary bladder inpatients with OAB or IC/BPS. Neurourol. Urodynam. 30: 417-420, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:417 / 420
页数:4
相关论文
共 27 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]   LUTS treatment: Future treatment options [J].
Andersson, K.-E. .
NEUROUROLOGY AND URODYNAMICS, 2007, 26 (06) :934-947
[3]   Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type a for the treatment of neurogenic or idiopathic detrusor overactivity [J].
Apostolidis, Apostolos ;
Jacques, Thomas S. ;
Freeman, Alex ;
Kalsi, Vinay ;
Popat, Roshni ;
Gonzales, Gwendoline ;
Datta, Soumendra N. ;
Ghazi-Noori, Shabnam ;
Elneil, Sohier ;
Dasqupta, Prokar ;
Fowler, Clare J. .
EUROPEAN UROLOGY, 2008, 53 (06) :1245-1253
[4]   Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder [J].
Chung, Shiu-Dong ;
Chiu, Bin ;
Kuo, Hann-Chorng ;
Chuang, Yao-Chi ;
Wang, Chung-Cheng ;
Guan, Zhonghong ;
Chancellor, Michael B. .
BJU INTERNATIONAL, 2010, 105 (05) :668-672
[5]   Histologic features in the urinary bladder wall affected from neurogenic overactivity -: A comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A [J].
Comperat, Eva ;
Reitz, Andre ;
Delcourt, Annick ;
Capron, Frederique ;
Denys, Pierre ;
Chartier-Kastler, Emmanuel .
EUROPEAN UROLOGY, 2006, 50 (05) :1058-1064
[6]   Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [J].
Di Silverio, F ;
Bosman, C ;
Salvatori, M ;
Albanesi, L ;
Pannunzi, LP ;
Ciccariello, M ;
Cardi, A ;
Salvatori, G ;
Sciarra, A .
EUROPEAN UROLOGY, 2005, 47 (01) :72-79
[7]   Histological and neurotrophic changes triggered by varying models of bladder inflammation [J].
Dupont, MC ;
Spitsbergen, JM ;
Kim, KB ;
Tuttle, JB ;
Steers, WD .
JOURNAL OF UROLOGY, 2001, 166 (03) :1111-1118
[8]   Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis [J].
Gonzalez, RR ;
Fong, T ;
Belmar, N ;
Saban, M ;
Felsen, D ;
Te, A .
JOURNAL OF UROLOGY, 2005, 173 (02) :630-634
[9]   The economic impact of overactive bladder syndrome in six Western countries [J].
Irwin, Debra E. ;
Mungapen, Laura ;
Milsom, Ian ;
Kopp, Zoe ;
Reeves, Penny ;
Kelleher, Con .
BJU INTERNATIONAL, 2009, 103 (02) :202-209
[10]   Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder [J].
Jang, Joon ;
Park, Eun Young ;
Seo, Seong Il ;
Hwang, Tae-Kon ;
Kim, Joon Chul .
BJU INTERNATIONAL, 2006, 98 (02) :435-439